Praxis Precision Medicine Analysts Raise Their Forecasts After Q4 Results

Benzinga

Feb 21

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) reported a wider-than-expected loss for the fourth quarter on Thursday.

The company posted quarterly losses of $3.50 per share which missed the analyst consensus estimate of losses of $3.08 per share.

“After a landmark fourth quarter, filled with a breadth of clinical and regulatory advancements across our portfolio, we started 2026 with two NDA submissions for ulixacaltamide and relutrigine. Pending their expected positive reviews, we will be positioned to transition into a commercial company,” said Marcio Souza, president and chief executive officer. “The other two programs in the clinic, vormatrigine and elsunersen, will both have topline results in the first half of 2026, keeping us on track for additional NDA submissions in the next two years. Together, these four assets have a revenue potential of over $20 billion.”

Praxis Precision Medicine shares fell 0.1% to trade at $303.00 on Friday.

These analysts made changes to their price targets on Praxis Precision Medicine following earnings announcement.

Wedbush analyst Laura Chico maintained Praxis Precision Medicine with an Underperform rating and raised the price target from $95 to $130.
Truist Securities analyst Joon Lee maintained the stock with a Buy and raised the price target from $500 to $700.
Baird analyst Joel Beatty maintained Praxis Precision Medicine with an Outperform rating and raised the price target from $275 to $433.

Considering buying PRAX stock? Here’s what analysts think:

Photo via Shutterstock

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2613296498"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2613296498\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2613296498?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-21 01:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2613296498","market":"us","top_or_hot":-1,"title":"Praxis Precision Medicine Analysts Raise Their Forecasts After Q4 Results","media":"Benzinga","content":"<html><body><p><strong><a href=\"https://laohu8.com/S/PRAX\">Praxis Precision Medicines, Inc.</a></strong> (NASDAQ:PRAX) reported a wider-than-expected loss for the fourth quarter on Thursday.</p>\n<p>The company posted quarterly losses of $3.50 per share which missed the analyst consensus estimate of losses of $3.08 per share.</p>\n<p>“After a landmark fourth quarter, filled with a breadth of clinical and regulatory advancements across our portfolio, we started 2026 with two NDA submissions for ulixacaltamide and relutrigine. Pending their expected positive reviews, we will be positioned to transition into a commercial company,” said Marcio Souza, president and chief executive officer. “The other two programs in the clinic, vormatrigine and elsunersen, will both have topline results in the first half of 2026, keeping us on track for additional NDA submissions in the next two years. Together, these four assets have a revenue potential of over $20 billion.”</p>\n<p>Praxis Precision Medicine shares fell 0.1% to trade at $303.00 on Friday.</p>\n<p>These analysts made changes to their price targets on Praxis Precision Medicine following earnings announcement.</p>\n<ul>\n<li>Wedbush analyst Laura Chico maintained Praxis Precision Medicine with an Underperform rating and raised the price target from $95 to $130.</li>\n<li>Truist Securities analyst Joon Lee maintained the stock with a Buy and raised the price target from $500 to $700.</li>\n<li>Baird analyst Joel Beatty maintained Praxis Precision Medicine with an Outperform rating and raised the price target from $275 to $433.</li>\n</ul>\n<p><strong>Considering buying PRAX stock? Here’s what analysts think:</strong> </p>\n<figure><img decoding=\"async\" height=\"504\" loading=\"lazy\" sizes=\"(max-width: 1024px) 100vw, 1024px\" src=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/02/20120943/image-503-1024x504.png\" srcset=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/02/20120943/image-503-1024x504.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/02/20120943/image-503-300x148.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/02/20120943/image-503-768x378.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/02/20120943/image-503.png 1233w\" width=\"1024\"/></figure>\n<p>Photo via Shutterstock</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Praxis Precision Medicine Analysts Raise Their Forecasts After Q4 Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPraxis Precision Medicine Analysts Raise Their Forecasts After Q4 Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2026-02-21 01:10</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p><strong><a href=\"https://laohu8.com/S/PRAX\">Praxis Precision Medicines, Inc.</a></strong> (NASDAQ:PRAX) reported a wider-than-expected loss for the fourth quarter on Thursday.</p>\n<p>The company posted quarterly losses of $3.50 per share which missed the analyst consensus estimate of losses of $3.08 per share.</p>\n<p>“After a landmark fourth quarter, filled with a breadth of clinical and regulatory advancements across our portfolio, we started 2026 with two NDA submissions for ulixacaltamide and relutrigine. Pending their expected positive reviews, we will be positioned to transition into a commercial company,” said Marcio Souza, president and chief executive officer. “The other two programs in the clinic, vormatrigine and elsunersen, will both have topline results in the first half of 2026, keeping us on track for additional NDA submissions in the next two years. Together, these four assets have a revenue potential of over $20 billion.”</p>\n<p>Praxis Precision Medicine shares fell 0.1% to trade at $303.00 on Friday.</p>\n<p>These analysts made changes to their price targets on Praxis Precision Medicine following earnings announcement.</p>\n<ul>\n<li>Wedbush analyst Laura Chico maintained Praxis Precision Medicine with an Underperform rating and raised the price target from $95 to $130.</li>\n<li>Truist Securities analyst Joon Lee maintained the stock with a Buy and raised the price target from $500 to $700.</li>\n<li>Baird analyst Joel Beatty maintained Praxis Precision Medicine with an Outperform rating and raised the price target from $275 to $433.</li>\n</ul>\n<p><strong>Considering buying PRAX stock? Here’s what analysts think:</strong> </p>\n<figure><img decoding=\"async\" height=\"504\" loading=\"lazy\" sizes=\"(max-width: 1024px) 100vw, 1024px\" src=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/02/20120943/image-503-1024x504.png\" srcset=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/02/20120943/image-503-1024x504.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/02/20120943/image-503-300x148.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/02/20120943/image-503-768x378.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/02/20120943/image-503.png 1233w\" width=\"1024\"/></figure>\n<p>Photo via Shutterstock</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PRAX","symbol_name":"Praxis Precision Medicines, Inc.","start_time":0,"source_url":"https://www.benzinga.com/analyst-stock-ratings/price-target/26/02/50756039/praxis-precision-medicine-analysts-raise-their-forecasts-after-q4-results","article_id":"2613296498","we_media_id":"1052270027","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2613296498","pubTimestamp":1771607439,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Benzinga","introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"summary":" ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PRAX":"Praxis Precision Medicines, Inc.","BK4139":"生物科技","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","IE0009355771.USD":"骏利亨德森环球生命科技A Acc"},"translate_title":"Praxis Precision Medicine分析师在第四季度业绩公布后上调预测","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PRAX":1},"content_text":"Praxis Precision Medicines, Inc. (NASDAQ:PRAX) reported a wider-than-expected loss for the fourth quarter on Thursday.\nThe company posted quarterly losses of $3.50 per share which missed the analyst consensus estimate of losses of $3.08 per share.\n“After a landmark fourth quarter, filled with a breadth of clinical and regulatory advancements across our portfolio, we started 2026 with two NDA submissions for ulixacaltamide and relutrigine. Pending their expected positive reviews, we will be positioned to transition into a commercial company,” said Marcio Souza, president and chief executive officer. “The other two programs in the clinic, vormatrigine and elsunersen, will both have topline results in the first half of 2026, keeping us on track for additional NDA submissions in the next two years. Together, these four assets have a revenue potential of over $20 billion.”\nPraxis Precision Medicine shares fell 0.1% to trade at $303.00 on Friday.\nThese analysts made changes to their price targets on Praxis Precision Medicine following earnings announcement.\n\nWedbush analyst Laura Chico maintained Praxis Precision Medicine with an Underperform rating and raised the price target from $95 to $130.\nTruist Securities analyst Joon Lee maintained the stock with a Buy and raised the price target from $500 to $700.\nBaird analyst Joel Beatty maintained Praxis Precision Medicine with an Outperform rating and raised the price target from $275 to $433.\n\nConsidering buying PRAX stock? Here’s what analysts think: \n\nPhoto via Shutterstock","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}